Document Type

Review Article


Among the common neurological disorders worldwide, Parkinson’s disease has a major share. Currently, only symptomatic therapies are available for it without any approved neuromodulation drugs as all the previously done disease modification trials have failed. There is a dire need for such therapies. Disease modification trials include all types of intervention targeting the degeneration process which underlies the disease process and thus slows it down or the treatment aim to regenerate or replace the neurons which are lost. There are many reasons for the failure of trials. This review emphasize the need for disease modification trials, causes of failure of trials, few prominent previously failed trails and review on-going clinical trials for disease modification. The aim of this review article is to highlight the importance and utmost need of development of neuroprotective agents for Parkinson’s disease through future research.

Included in

Neurology Commons